Saturday 17 October 2026 Export KPTI’s income statement to Excel — free account

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 11.9%, EPS grew 46.3%, free cash flow fell 33.3% and total debt rose 36.6%, each against the same quarter a year earlier.

0.39 0.04 +11.43%

Follow KPTI

Alert me

Market cap: $8.0M
P/E: 0.0×
Fwd P/E: −2.1×
Dividend yield: —
F-score: 3/9
Altman Z: −23.89
Beneish M: −8.05
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.25

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	2	2	3	1	6	—	1	—	1	1

Insider Ownership 34.86%

Capital & Financial Ratios $m

Market Cap 7.95

Revenue 146.62

Net Income (224.74)

Free Cash Flow (65.35)

Net Debt 184.84

Current Ratio 0.79

Debt/Equity (0.76)

P/E ratio 0.00

Fwd P/E (2.08)

P/S ratio 0.08

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 72.99%

Next Y EPS Growth 53.13%

Next Y revenue growth (7.17%)

Next 5Y EPS Growth 60.92%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.11%

10-year low 10-year high

EV/Sales against its own 10 years 24.59%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	192	109	64	65
Receivables	27	31	26	30
Inventory	3	5	4	4
Other	—	—	—	—
	234	156	103	106

	2023	2024	2025	Q'26
Payables	3	5	4	8
ST’ Debt	—	24	21	40
Other	2	2	2	6
	69	92	92	134

Compound Annual Growth %

	10y	5y	3y
Sales	89.09%	6.21%	(2.39%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	35	33	—	—	—
’25	30	38	44	34	146
’24	33	43	39	31	145
’23	39	38	36	34	146
’22	48	40	36	34	157
’21	23	23	38	126	210
’20	18	34	21	35	108

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(25)	—	—	—
’25	(39)	(19)	(6)	(12)	(75)
’24	(44)	(38)	(19)	(26)	(127)
’23	(19)	(26)	(30)	(19)	(93)
’22	(59)	(35)	(28)	(27)	(150)
’21	(53)	(56)	(24)	25	(107)
’20	(45)	(40)	(44)	(31)	(160)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(25)	—	—	—
’25	(39)	(19)	(6)	(12)	(75)
’24	(44)	(38)	(19)	(26)	(128)
’23	(19)	(26)	(30)	(19)	(93)
’22	(59)	(35)	(28)	(27)	(150)
’21	(53)	(56)	(24)	25	(107)
’20	(45)	(40)	(44)	(31)	(160)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.91)	(2.32)	—	—	—
’25	(2.77)	(4.32)	(3.82)	(7.01)	(17.93)
’24	(4.80)	2.31	(3.90)	(3.60)	(9.04)
’23	(4.50)	(4.35)	(4.50)	(5.40)	(18.74)
’22	(7.95)	(9.30)	(6.75)	(6.45)	(30.28)
’21	(11.54)	(10.64)	(10.34)	6.90	(24.74)
’20	(11.69)	(9.45)	(10.94)	(8.85)	(40.78)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	72.45	112.20	120.15	58.80	200.85	66.30	36.75	9.26	8.72	3.51	Analyst estimates 2026–2028 Powerpack
	High	209.55	219.45	325.65	300.00	444.15	270.00	220.95	73.05	29.25	12.45
People
People	Employees	108	154	332	347	432	442	385	325	279	228
	Revenue/emp, $m	0.00	0.01	0.09	0.12	0.25	0.47	0.41	0.45	0.52	0.64
Income, $m
Income, $m	Revenue	0	2	30	41	108	210	157	146	145	146
	Gross margin, %	100.00	100.00	100.00	94.11	97.50	98.38	96.68	96.62	95.86	95.93
	EBT	(109)	(129)	(178)	(200)	(196)	(124)	(165)	(143)	(76)	(196)
	EBT margin, %	(71,063.64)	(8,032.46)	(588.02)	(487.98)	(181.31)	(59.01)	(105.00)	(97.77)	(52.58)	(134.18)
	Net income	(110)	(129)	(178)	(200)	(196)	(124)	(165)	(143)	(76)	(196)
	Depreciation	2	2	2	7	10	3	1	(3)	4	10
Per share, $
Per share, $	Revenue	0.06	0.52	8.01	9.90	22.49	41.82	28.76	19.17	17.88	13.36
	Earnings	(43.78)	(42.13)	(47.08)	(48.28)	(40.78)	(24.74)	(30.28)	(18.74)	(9.45)	(17.93)
	Cash flow	(33.72)	(24.08)	(42.01)	(46.18)	(33.35)	(21.35)	(27.39)	(12.17)	(15.69)	(6.89)
	Capex	(0.03)	(0.02)	(0.62)	(0.05)	(0.03)	(0.04)	(0.02)	0.00	(0.02)	0.00
	Free cash flow	(33.75)	(24.10)	(42.64)	(46.23)	(33.38)	(21.39)	(27.41)	(12.17)	(15.71)	(6.89)
	Book value	64.82	42.29	48.37	12.04	10.52	(15.88)	(3.05)	(17.88)	(22.89)	(26.79)
	Shares, m	3	3	4	4	5	5	5	8	8	11
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2,021.82	275.76	17.55	29.06	10.32	2.31	1.70	0.71	0.57	0.55
	P/B	2.23	3.52	2.91	23.87	22.07	0.00	0.00	0.00	0.00	0.00
	EV/Sales	1,298.06	186.97	10.11	25.35	9.10	2.00	1.02	0.58	1.11	1.67
	EV/FCF	(2.75)	(4.19)	(1.90)	(5.43)	(6.13)	(3.91)	(1.08)	(0.92)	(1.26)	(3.23)
Cash, $m
Cash, $m	Operating cash flow	(84)	(74)	(159)	(191)	(160)	(107)	(150)	(93)	(127)	(75)
	Capex	0	0	(2)	0	0	0	0	—	0	—
	Free cash flow	(84)	(74)	(161)	(191)	(160)	(107)	(150)	(93)	(128)	(75)
Balance, $m
Balance, $m	Working capital	115	99	288	232	216	202	284	164	64	11
	Total debt	—	—	103	112	120	172	173	171	187	227
	Net debt	(130)	(147)	(226)	(152)	(132)	(63)	(106)	(21)	79	163
	Shareholders’ equity	162	129	183	50	51	(80)	(17)	(136)	(186)	(293)
Returns, %
Returns, %	ROA	(55.37)	(71.52)	(68.42)	(62.75)	(64.56)	(40.13)	(49.83)	(47.81)	(37.75)	(143.71)
	ROIC	(211.70)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(60.77)	(88.43)	(114.13)	(171.36)	(391.29)	852.05	343.18	187.23	47.43	81.86

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADIL Adial Pharmaceuticals, Inc.	$8.3M	— (loss-making)	—	—	n/m	−263.66% (below 0%: shrinking)	0.00%	0.00%	Compare
BOLT Bolt Biotherapeutics, Inc.	$8.2M	— (loss-making)	— (loss-making)	−99.72% (below 0%: shrinking)	n/m	+38.87% (above 0%: growing)	100.00%	(167,480.00%)	Compare
SNTI Senti Biosciences, Inc.	$8.1M	— (loss-making)	— (loss-making)	−98.68% (below 0%: shrinking)	n/m	−7.48% (below 0%: shrinking)	100.00%	(85,229.41%)	Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR	$8.1M	— (loss-making)	—	—	n/m	−510.28% (below 0%: shrinking)	0.00%	0.00%	Compare
XTLB XTL Biopharmaceuticals Ltd.	$8.1M	— (loss-making)	—	−39.32% (below 0%: shrinking)	n/m	+46.78% (above 0%: growing)	0.00%	0.00%	Compare
KPTI Karyopharm Therapeutics Inc.	$8.0M	— (loss-making)	— (loss-making)	−11.86% (below 0%: shrinking)	n/m	−33.34% (below 0%: shrinking)	96.75%	(67.38%)
CNSP CNS Pharmaceuticals, Inc.	$7.9M	— (loss-making)	—	—	n/m	+33.70% (above 0%: growing)	0.00%	0.00%	Compare
APRE Aprea Therapeutics, Inc.	$7.8M	— (loss-making)	— (loss-making)	−98.40% (below 0%: shrinking)	n/m	−5.22% (below 0%: shrinking)	100.00%	0.00%	Compare
SNGX Soligenix Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.89% (below 0%: shrinking)	n/m	+37.83% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$8.1M	—	—	−98.68%	—	+14.24%	0.00%	0.00%

All 614 Biotechnology stocks →

Karyopharm Therapeutics Inc. (KPTI) key facts

Strength: Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024.
Karyopharm Therapeutics Inc. (KPTI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KPTI traded at $0.39, a market capitalization of $8.0 million.
Return on equity was 81.9% and debt-to-equity -0.76.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −23.89 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.